Gynecologic Cancers: Ovarian Cancer

FP essentials · 2025 · vol. 558 , pp. 21–25 · PMID:41252823 · W4416411685
Review OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-10-13 ⓘ

This review addresses ovarian cancer, the most lethal gynecologic malignancy, by highlighting diagnostic challenges, risk factors like BRCA mutations, and clinical management strategies including CA-125 testing to improve survival rates.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Ovarian cancer, although ranking lower in overall incidence among cancers in the United States, is the most lethal gynecologic malignancy, with a 5-year survival rate of 50.9% despite advances in therapies. Two of the largest challenges in management are the lack of effective screening and the vague symptoms of the disease. Most ovarian cancers are diagnosed after metastasis has occurred. Genetic variants, such as BRCA1 and BRCA2, are strong risk factors, accounting for 10% to 15% of all ovarian cancers. Physicians should consider ovarian cancer in patients with pelvic pain or rapidly increasing abdominal girth. Initial workup includes a bimanual examination palpating for pelvic mass, an abdominal examination for ascites, transvaginal ultrasonography, and a cancer antigen 125 level. Referral to gynecologic oncology is appropriate for patients with findings concerning for malignancy on ultrasonography or with ascites or findings of metastasis. For patients with elevated cancer antigen 125 levels, referral is also warranted. Although there have not been significant advances in early detection, survival rates have improved because of better management and treatment. Family physicians play an important role by providing long-term continuous relationships with patients that may improve recognition of the disease and by providing support during treatment.

My notes (saved in your browser only)

MeSH descriptors

Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms CA-125 Antigen CA-125 Antigen Early Detection of Cancer Family Practice Female Humans Risk Factors

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-05-11T05:02:20.987148+00:00
pubmed
last seen: 2026-10-08T21:52:33.274341+00:00
License: CC0 · commercial use OK